ライブ
Endpoints News#ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effectsIlluminaIllumina (ILMN) Valuation Check After New Oncology Collaborations And MRD Research Launch - Yahoo FinanceFierceBiotechADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect10x Genomics News10x Genomics (TXG) Is Up 9.7% After Momentum Rally Despite Weak Fundamentals - What's Changed - simplywall.stFierceBiotechADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetesClinical OMICsGLP-1 Drugs Lower Risk of Death by 44% in Obesity and Autoimmune DiseaseCellDeep-sea megafauna co-opts microbial energy metabolism genes to withstand ultra-long starvationCellReplaying germinal center evolution on a quantified affinity landscapeCellXenophagocytosis blockade enhances interspecies chimerismFierceBiotechADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buyEndpoints News#ADA26: Pfizer monthly shot shows effect on obesity, diabetesEndpoints News#ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this year
FierceBiotech 2025年12月12日

Obesity biotech Zealand seeks partners to ‘take therapies directly to the brain’

Obesity biotech Zealand seeks partners to ‘take therapies directly to the brain’

原文
本文は利用できません。元の情報源をご確認ください。